Cancer Therapy
Tumor angiogenesis and proliferation is attenuated by tetrathiomolybdate analogue
Published in Blood Weekly, October 19th, 2006
"A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level," scientists in the United States reported.
"The effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro. The antiangiogenic activity of ATN-224 was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-10-19)
More Articles from Blood Weekly
- Blood Separation
Polyurethane foaming membranes recover CD34+ cells from peripheral blood - Nosocomial Infections
Thirty percent of nosocomial infections can be avoided - Sepsis
Role of protein C in sepsis clarified - Tissue Engineering
Osteogenic characteristics of platelet-enriched fibrin glue superior to platelet-rich plasma - Transfusion Medicine
G-CSF mobilized granulocyte transfusion feasible and safe in pediatric bacterial sepsis - Acute Myeloid Leukemia
Acute myeloid leukemia-associated MLL partial tandem duplications persist lifelong - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
